These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
166 related items for PubMed ID: 17097980
1. Hepatitis C virus recurrence after liver transplantation: influence of immunosuppressive regimens on viral load and liver histology. Oton E, Barcena R, Castillo M, Barreales M, Blesa C, Moreno-Planas JM, Barrios C, Garrido A, Cuervas V. Transplant Proc; 2006 Oct; 38(8):2499-501. PubMed ID: 17097980 [Abstract] [Full Text] [Related]
2. Scarce influence of corticosteroid boluses on long-term viral load and liver histology in transplanted patients with recurrent hepatitis C. Barcena R, Oton E, Barreales M, Castillo M, Blesa C. Transplant Proc; 2006 Oct; 38(8):2502-4. PubMed ID: 17097981 [Abstract] [Full Text] [Related]
6. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB, Fitzsimmons WE, Uleman C. Liver Transpl; 2004 Oct; 10(10):1258-62. PubMed ID: 15376310 [Abstract] [Full Text] [Related]
7. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Soldevila-Pico C, Machicao VI, Cabrera R, Reed AI, Liu C, Nelson DR. Liver Transpl; 2006 Jan; 12(1):51-7. PubMed ID: 16382464 [Abstract] [Full Text] [Related]
8. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Yoshida EM, Lilly LB, Marotta PJ, Mason AL, Bilodeau M, Vaillancourt M. Ann Hepatol; 2013 Jan; 12(2):282-93. PubMed ID: 23396740 [Abstract] [Full Text] [Related]
9. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mühlbacher F, Leonardi L, Cillo U. Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875 [Abstract] [Full Text] [Related]
12. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Berenguer M, Aguilera V, Prieto M, San Juan F, Rayón JM, Benlloch S, Berenguer J. Liver Transpl; 2006 May; 12(5):762-7. PubMed ID: 16528713 [Abstract] [Full Text] [Related]
14. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Yilmaz N, Shiffman ML, Stravitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Coterell A, Maluf D, Posner MP, Fisher RA. Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360 [Abstract] [Full Text] [Related]
15. University of Modena experience in HIV-positive patients undergoing liver transplantation. Di Benedetto F, Tarantino G, De Ruvo N, Cautero N, Montalti R, Guerrini GP, Ballarin R, Spaggiari M, Smerieri N, Serra V, Rompianesi G, D'Amico G, Mimmo A, Iemmolo RM, Codeluppi M, Cocchi S, Guaraldi G, Gerunda GE. Transplant Proc; 2011 May; 43(4):1114-8. PubMed ID: 21620066 [Abstract] [Full Text] [Related]
16. Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. Muzi F, Orlando G, Ielpo B, Anselmo A, Sabato Ceraldi S, de Liguori Carino N, Manzia T, D'Andria D, Tariciotti L, Angelico M, Tisone G. Transplant Proc; 2005 May; 37(4):1705-7. PubMed ID: 15919438 [Abstract] [Full Text] [Related]
17. Calcineurin inhibition and disease recurrence in the hepatitis C virus-positive liver transplant recipient. Pollard S. Liver Int; 2004 Oct; 24(5):402-6. PubMed ID: 15482334 [Abstract] [Full Text] [Related]
18. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. Dharancy S, Podevin P, Aoudjehane L, Batteux F, Rosenberg AR, Soubrane O, Calmus Y, Conti F. Transplantation; 2007 Apr 15; 83(7):906-11. PubMed ID: 17460561 [Abstract] [Full Text] [Related]
19. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Kamar N, Abravanel F, Selves J, Garrouste C, Esposito L, Lavayssière L, Cointault O, Ribes D, Cardeau I, Nogier MB, Mansuy JM, Muscari F, Peron JM, Izopet J, Rostaing L. Transplantation; 2010 Feb 15; 89(3):353-60. PubMed ID: 20145528 [Abstract] [Full Text] [Related]
20. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, Piscaglia F, Tamè M, Pinna AD. Liver Transpl; 2009 Jul 15; 15(7):782-9. PubMed ID: 19562715 [Abstract] [Full Text] [Related] Page: [Next] [New Search]